Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,253.9
6.8 (0.21%)

 

  • STI Straits Times Index
    3,253.9
    6.8 (0.21%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,578.0
    -9.3 (-0.59%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,341.0
    355.7 (1.27%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,060.8
    8.6 (0.28%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    24,031.3
    166.8 (0.70%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,233.5
    -4.7 (-0.08%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,267.2
    27.6 (1.23%)
    Index delayed 20 minutes
  • XAO XAO
    7,249.0
    68.5 (0.95%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,638.5M
  • Value: 1,045.8M
  • Rise: 151
  • Fall: 154
  • Unch: 514

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.098+0.006
AsiaMedic0.016-0.002
Healthway Med0.043+0.003
P5 Capital0.033-0.002
Ntegrator Intl0.015+0.002
AusGroup^0.044-0.001
YZJ Shipbldg SGD1.090-0.010
Thomson Medical0.064+0.001
DISA0.002-0.001
Golden Agri-Res0.230-

World Indices

World Indices
Name Last Change
Nasdaq 9,370.8 -18.1
HSI 28,341.0 +355.7
HSCEI 11,174.7 +204.6
Jakarta 6,233.5 -4.7
Nikkei 225 24,031.3 +166.8
SSE Comp 3,060.8 +8.6
Shanghai A 3,207.1 +9.0
Shanghai B 257.5 +0.2
PSE Comp 0.0
KOSPI 2,267.2 +27.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

MYOVANT SCIENCES LTD MYOVANT SCIENCES LTD.
Updated on 21 Jan 2020 (End of trading day)
Last (USD): 14.000 Change: +0.120 High: 14.170 Remarks: -
Change (%): +0.86 Low: 13.650
Open 13.900 Yesterday's Close 13.88
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 829,622 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.05034 Trailing EPS (USD) e -3.16818 NAV (USD) b 0.1924
PE a - Trailing PE f - Price / NAV b 72.7651
Dividend (USD) d - Cash In Hand (USD) g 1.4538 Issued & Paid-up Shares c 89,679,000
Dividend Yield (%) d - Price / Cash In Hand g 9.630 Treasury Shares h -
Beta - 75 Daysi -0.182 R-Squared - 75 Days(%)i 0.08 Market Cap (M) 1,255.506
Beta - 500 Daysi 0.232 R-Squared - 500 Days (%)i 0.26 Enterprise Value (M) 1,208.563
Piotroski F Score 0 Exchange Code MYOV Par Value ( $ ) n.a.
52 Weeks Volatility (%) 111.51 Free Float (%) 35.5
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 07 Jan 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 24 Oct 2016.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference MYOVANT SCIENCES LTD NYSE 1,255.506 - - 72.7651 -
Industry Biotechnology NYSE 5,553.474 18709.065 53.884 5.4678 0.569
Local Peer AGILENT TECHNOLOGIES INC NYSE 27,795.499 87.961 25.953 5.8541 0.682
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 2,959.088 47.194 688.160 2.8590 -
Local Peer KADMON HLDGS INC NYSE 730.927 - - 19.1312 -
Local Peer ARCUS BIOSCIENCES INC NYSE 459.507 - - 2.5928 -
Local Peer ENZO BIOCHEM INC NYSE 120.319 48.338 146.374 1.5361 -
Global Peer AMGEN INC NASDAQ 141,178.118 16.819 17.501 12.9201 2.355
Global Peer CSL ASX 140,022.597 52.190 52.189 18.7117 0.860
Global Peer GILEAD SCIENCES INC NASDAQ 79,236.345 14.525 29.423 3.8457 3.689
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 60,170.529 28.702 28.068 11.4536 -
Global Peer BIOGEN INC NASDAQ 51,821.138 11.696 9.604 3.7026 -
Global Peer ILLUMINA INC NASDAQ 48,264.510 58.432 49.604 10.8728 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 39,933.892 16.337 18.624 3.8016 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,008.096 322.269 17.009 2.4122 -
Global Peer SINO BIOPHARM HKEx 151,866.775 14.173 14.710 4.5227 0.606
Other Global Peers SEATTLE GENETICS INC (NASDAQ), WUXI BIO (HKEx), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), BEIGENE (HKEx), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), REPLIGEN CORP (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), Lonza (SGX), GENSCRIPT BIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), 3SBIO (HKEx), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), VIELA BIO INC (NASDAQ), INSMED INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), HAOHAI BIOTEC (HKEx), ALPHAMAB-B (HKEx), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ALECTOR INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEXTCURE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), POLYNOVO LIMITED (ASX), ENANTA PHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), KARYOPHARM THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD (ASX), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), OPKO HEALTH INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), MESOBLAST LTD (ASX), SANGAMO THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), RADIUS HEALTH INC (NASDAQ), VIVA BIOTECH (HKEx), ACHILLION PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ASCENTAGE-B (HKEx), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), OMEROS CORP (NASDAQ), CYTOKINETICS INC (NASDAQ), AVROBIO INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), IMMUNOGEN INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), ARDELYX INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MACROGENICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), NANOVIRICIDES INC (NYSE American), AGENUS INC (NASDAQ), SINOMAB BIO-B (HKEx), VIKING THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), TRANSLATE BIO INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), ANAPTYSBIO INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), CABALETTA BIO INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), RECRO PHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), LEE'S PHARM (HKEx), CYTOMX THERAPEUTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), MEDICINOVA INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GERON CORP (NASDAQ), DPHARMA (Bursa), KAMADA (NASDAQ), NEXT SCIENCE LTD (ASX), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), TELIX PHARMACEUTIC (ASX), PFENEX INC (NYSE American), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), SERES THERAPEUTICS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), BBI LIFE SCI (HKEx), SYNDAX PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), AFFIMED N V (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), XOMA CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), IMV INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ATHERSYS INC (NASDAQ), CHIASMA INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), PROTAGONIST THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ARAVIVE INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), AVALON GLOBOCARE CORP (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), NEUROBO PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), UNI-BIO GROUP (HKEx), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CEL-SCI CORP (NYSE American), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), ADURO BIOTECH INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), OTONOMY INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), BELLICUM PHARMACEUTICALS (NASDAQ), IMUGENE LIMITED (ASX), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SYNLOGIC INC (NASDAQ), COHBAR INC (NASDAQ), SESEN BIO INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), NEWLINK GENETICS CORP (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ORGENESIS INC (NASDAQ), TREVENA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), VACCINEX INC (NASDAQ), EQUILLIUM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ALPINE IMMUNE SCIENCES INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ORTHOCELL LIMITED (ASX), GENOCEA BIOSCIENCES INC (NASDAQ), INMUNE BIO INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ISORAY INC (NYSE American), RESTORBIO INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ADVAXIS INC (NASDAQ), CT ENTERPRISE (HKEx), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ZAFGEN INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), MERRIMACK PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOSINO BIO-TEC (HKEx), CELLDEX THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), OCUGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ANTEOTECH LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), OUTLOOK THERAPEUTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), IBIO INC (NYSE American), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), REGENT PACIFIC (HKEx), MEMPHASYS LTD (ASX), BIOTRON (ASX), AETERNA ZENTARIS INC (NASDAQ), BIONOMICS LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), GENETIC TECHNOLOGIES (ASX), TALI DIGITAL LIMITED (ASX), VAXART INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), EXTRAWELL PHAR (HKEx), ORAGENICS INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), BIO-PATH HOLDINGS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), MIRAGEN THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PRECIPIO INC (NASDAQ), SENESTECH INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), PATRYS LIMITED (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), BIOCEPT INC (NASDAQ), TOCAGEN INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), REGENEUS LTD (ASX), CYCLACEL PHARMA IN (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), TROVAGENE INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ADALTA LTD (ASX), OPGEN INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), SIENNA CANCER DIAGNOSTICS LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), MEDIBIO LIMITED (ASX), QT Vascular (SGX), PHIO PHARMACEUTICALS CORP (NASDAQ), MGRC (Bursa), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), TBG DIAGNOSTICS LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.150
+1.08 %
10 Days --0.290
-2.03 %
20 Days --3.170
-18.46 %
Medium Term Return 3 Months -+9.180
+190.46 %
6 Months -+6.070
+76.54 %
1 Year --3.870
-21.66 %
Long Term Return 2 Years -+0.980
+7.53 %
3 Years -+3.150
+29.03 %
Annualised Return Annualised --
+8.87 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 4.140 - 26.020 Change From 1 Year Low +9.860 % Change From 1 Year Low (%) +238.16
Change From 1 Year High -12.020 % Change From 1 Year High (%) -46.20
2 Years Range 4.140 - 27.450 Change From 2 Years Low +9.860 % Change From 2 Years Low (%) +238.16
Change From 2 Years High -13.450 % Change From 2 Years High (%) -49.00
5 Years Range 4.140 - 27.450 Change From 5 Years Low +9.860 % Change From 5 Years Low (%) +238.16
Change From 5 Years High -13.450 % Change From 5 Years High (%) -49.00
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Jan 2020 13.900 14.170 13.650 14.000 829,622 -
17 Jan 2020 14.600 14.850 13.790 13.880 751,656 -
16 Jan 2020 13.830 14.800 13.830 14.620 647,693 -
15 Jan 2020 14.000 14.225 13.400 13.850 807,208 -
14 Jan 2020 14.110 14.380 13.650 14.130 806,467 -
13 Jan 2020 14.410 14.500 13.850 14.060 550,042 -
10 Jan 2020 14.240 14.850 14.230 14.410 525,529 -
09 Jan 2020 14.330 14.338 13.800 14.290 484,635 -
08 Jan 2020 13.900 14.560 13.660 14.290 551,512 -
07 Jan 2020 14.450 14.514 13.900 14.010 533,654 -
06 Jan 2020 14.090 14.740 13.800 14.430 612,969 -
03 Jan 2020 14.550 14.648 14.100 14.110 794,636 -
02 Jan 2020 15.630 15.730 14.610 14.760 870,564 -
31 Dec 2019 15.480 15.820 15.260 15.520 701,042 -
30 Dec 2019 15.580 15.790 14.990 15.650 941,349 -
27 Dec 2019 16.500 16.500 15.700 15.810 592,237 -
26 Dec 2019 17.000 17.315 16.300 16.410 759,404 -
24 Dec 2019 17.300 17.740 16.860 17.170 580,181 -
23 Dec 2019 16.000 17.490 15.920 17.060 1,429,601 -
20 Dec 2019 15.970 16.110 15.565 15.900 1,121,080 -
19 Dec 2019 16.030 16.310 15.510 16.070 1,299,247 -
18 Dec 2019 16.370 17.210 15.620 15.880 1,379,267 -
Summary
Current 2 Weeks
(07 Jan 2020 to 21 Jan 2020)
14.450 14.850 13.400 14.000 6,488,018 -
Previous 2 Weeks
(20 Dec 2019 to 06 Jan 2020)
15.970 16.110 13.400 14.430 8,403,063 -
4 Weeks from
(21 Nov 2019 to 19 Dec 2019)
12.250 14.850 11.280 16.070 53,290,137 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.